Anatara takes next step in testing its answer to US$8 billion global IBS issue

Anatara Lifesciences (ASX:ANR) has met the projected milestone to finalise a draft protocol for a human clinical trial for its GaRP dietary supplement in the treatment of irritable bowel syndrome (IBS).